Rotavirus vaccines

被引:11
作者
Lynch, M [1 ]
Bresee, JS [1 ]
Gentsch, JR [1 ]
Glass, RI [1 ]
机构
[1] Ctr Dis Control & Prevent, Viral Gastroenteritis Sect, Resp & Enteric Viruses Branch, Div Viral & Rickettsial Dis,Natl Ctr Infect Dis, Atlanta, GA 30333 USA
关键词
D O I
10.1097/00001432-200010000-00011
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
The past few years have seen important developments in understanding the epidemiological and virological characteristics of rotaviruses, and rapid progress has been made in rotavirus vaccine development, but further challenges remain before a vaccine is introduced into widespread use. The licensure of the first rotavirus vaccine, a tetravalent rhesus-based rotavirus vaccine, in the United States in 1998, marked a significant advance in preventing the morbidity associated with rotavirus diarrhea. The association between the tetravalent rhesus-based rotavirus vaccine and intussusception has created significant hurdles as well as new opportunities to study the pathogenesis of rotavirus and rotavirus vaccine infection. Several other rotavirus vaccine candidates are in late stages of development, and results from trials have been encouraging. Curr Opin Infect Dis 13:495-501. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:495 / 502
页数:8
相关论文
共 86 条
[1]
[Anonymous], 1999, MMWR Recomm Rep, V48, P1
[2]
Argüelles MH, 2000, J CLIN MICROBIOL, V38, P252
[3]
AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307
[4]
EVALUATION OF RHESUS ROTAVIRUS MONOVALENT AND TETRAVALENT REASSORTANT VACCINES IN US CHILDREN [J].
BERNSTEIN, DI ;
GLASS, RI ;
RODGERS, G ;
DAVIDSON, BL ;
SACK, DA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (15) :1191-1196
[5]
Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial [J].
Bernstein, DI ;
Sack, DA ;
Rothstein, E ;
Reisinger, K ;
Smith, VE ;
O'Sullivan, D ;
Spriggs, DR ;
Ward, RL .
LANCET, 1999, 354 (9175) :287-290
[6]
G and P genotyping of rotavirus strains circulating in France over a three-year period: Detection of G9 and P[6] strains at low frequencies [J].
Bon, F ;
Fromantin, C ;
Aho, S ;
Pothier, P ;
Kohli, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (04) :1681-1683
[7]
Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries [J].
Bresee, JS ;
Glass, RI ;
Ivanoff, B ;
Gentsch, JR .
VACCINE, 1999, 17 (18) :2207-2222
[8]
Centers for Disease Control and Prevention (CDC), 1999, MMWR MORB MORTAL WKL, V48, P1007
[9]
Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles [J].
Chen, SC ;
Jones, DH ;
Fynan, EF ;
Farrar, GH ;
Clegg, JCS ;
Greenberg, HB ;
Herrmann, JE .
JOURNAL OF VIROLOGY, 1998, 72 (07) :5757-5761
[10]
Comparative amino acid sequence analysis of the outer capsid protein VP4 from four lapine rotavirus strains reveals identity with genotype P[14] human rotaviruses [J].
Ciarlet, M ;
Estes, MK ;
Conner, ME .
ARCHIVES OF VIROLOGY, 1997, 142 (05) :1059-1069